Based on the substantial difference between the magnitude of Gal-9 in the plasma of COVID-19 patients and in HCs, we hypothesized that the plasma Gal-9 level could be used as a surrogate marker to differentiate COVID-19 patients from HCs. The gene discussed is LGALS9; the disease is COVID-19.